ClinicalTrials.gg
Drug

Lorlatinib clinical trials

Also written PF-06463922 and Lorbrena.

studies test it
45
open now
13
in phase 3
3
first study started
2014

How each study uses lorlatinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the lorlatinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
2 Nov 2018 · LORBRENA · NDA 210868 (FDA, Drugs@FDA)
European Union
6 May 2019 · Lorviqua · EMEA/H/C/004646 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Lorlatinib
35
Lorviqua
4
Lorlatinib 100 mg
3
2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-
2

Brand

Lorbrena
6

Development codes

PF-06463922
15

Studies by the year they started

45 studies that test it; most in 2020 (6)

Studies that test lorlatinib, by start year
YearStudies
20141
20153
20164
20174
20182
20195
20206
20212
20223
20234
20243
20255
20263

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
15
Phase 2
23
Phase 3
3
Phase 4
5
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 20 · Other 25

Pfizer (17) · Guangdong Association of Clinical Trials (4) · Intergroupe Francophone de Cancerologie Thoracique (2) · Memorial Sloan Kettering Cancer Center (1) · CStone Pharmaceuticals (1) · Guangdong Provincial People's Hospital (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · University of Milano Bicocca (1)

Often tested with

Tested in the same studies.

Axitinib (2) · Crizotinib (2) · Alectinib (2) · Talazoparib (2) · Ramucirumab (1) · Temozolomide (1) · Osimertinib (1) · Sacituzumab tirumotecan (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 3

Studies that test lorlatinib.

Studies

Open first, then newest update. How each study uses lorlatinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 45

See all 45 studies that test lorlatinib →

Given beside what is tested · 5 — lorlatinib is usual care or a partner of the new treatment

Codes

What other systems call lorlatinib · ClinicalTrials.gg INT000046

  • MeSH (NLM) C000590786lorlatinibConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) OSP71S83EULORLATINIBConfirmed FDA, NLM, Wikidata
  • RxNorm 2103164Confirmed FDA, Wikidata
  • Wikidata Q27285820lorlatinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C113655LorlatinibOne source FDA
  • DrugBank DB12130One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.